幽门螺杆菌对克拉霉素、甲硝唑和左氧氟沙星的耐药率及其相关耐药基因突变特征

doi:10.13481/j.1671-587X.20220311

Abstract

Abstract:

Objective： To detect the drug resistance rates of Helicobacter pylori （Hp） to three common antibiotics，and to explore the mutation forms of drug resistance genes in order to provide the basis for elucidating the molecular mechanism of drug resistance.

Methods

The gastric mucosa samples from 35 patients with chronic gastritis or peptic ulcer were isolated and cultured to identify Hp.The minimal inhibitory concentrations （MIC） of Hp to clarithromycin， metronidazole and levofloxacin were detected by the agar dilution method and Hp was divided into sensitive group and resistant group according to the results of the drug sensitivity test.The clarithromycin resistance gene 23S rRNA， metronidazole resistance gene rdxA， and levofloxacin resistance gene gyrA were amplified by PCR method. The nucleotide and amino acid mutations were analyzed after the sequencing of PCR purified product.

Results

After cultured for 3－5 d， smooth， translucent， needle-like colonies could be seen on the plate of Hp strain. All 35 Hp strains were resistant to metronidazole and levofloxacin， the resistance rate to clarithromycin was the highest（80%）. Compared with the sensitive strains， all the clarithromycin- resistant strains had gene mutations. The most common mutation site of the 23S rRNA gene was A2143G， followed by mutation sites A2223G and A2142G+A2164G. The rdxA gene of metronidazole resistant strains mainly had missense mutations， followed by frameshift mutations and nonsense mutations. The N87K mutation in the gyrA gene of levofloxacin resistant strains was the highest， followed by the D91N mutation， N87I， D91G， and N87K+D143E mutations，but 17.1% of the resistant strains did not have any site mutations.

Conclusion

The resistance rates of Hp to clarithromycin， metronidazole， and levofloxacin are high， and the mutations of related drug resistance genes are the main cause of the antibiotic resistance. Screening these mutations may help to prevent the antibiotic resistance and select the appropriate antimicrobials to eradicate Hp.

Key words: Helicobacter pylori, Drug resistance, Clarithromycin, Metronidazole, Levofloxacin

CLC Number:

R446.5

Shunjia SONG,Xinying WANG,Feifei JIANG,Huijian JIA,Yuan ZHAO,Zhiping YANG,Liyuan SUN,Yundong ZHAO. Resistance rates of Helicobacter pylori to clarithromycin, metronidazole, and levofloxacin and mutation characteristics of their related drug resistance genes[J].Journal of Jilin University(Medicine Edition), 2022, 48(3): 630-637.

Figures/Tables 13

Tab. 1

Fig. 1

Fig.2

Fig. 3

Tab. 2

Fig. 4

Fig. 5

Fig. 6

Fig. 7

Tab. 3

Tab. 4

Fig. 8

Tab. 5

References 28

1	KAO C Y， SHEU B S， WU J J. Helicobacter pylori infection： an overview of bacterial virulence factors and pathogenesis［J］. Biomed J， 2016， 39（1）： 14-23.
2	BEHESHTIROUY S， EYVAZI S， TARHRIZ V. Evaluation of mutations in 23S rRNA， rdxA and frxA genes of Helicobacter pylori in paraffin-embedded gastric biopsy specimens from Iranian gastric cancer and gastritis patients［J］.J Gastrointest Cancer，2021，52（1）： 207-211.
3	NAGY P， JOHANSSON S， MOLLOY-BLAND M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA［J］. Gut Pathog， 2016， 8： 8.
4	ARSLAN N， YıLMAZ Ö， DEMIRAY-GÜRBÜZ E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection［J］. World J Gastroenterol， 2017， 23（16）： 2854-2869.
5	GRAHAM D Y， FISCHBACH L. Helicobacter pylori treatment in the era of increasing antibiotic resistance［J］. Gut， 2010， 59（8）： 1143-1153.
6	BOYANOVA L， HADZHIYSKI P， KANDILAROV N，et al. Multidrug resistance in Helicobacter pylori： current state and future directions［J］. Expert Rev Clin Pharmacol， 2019， 12（9）： 909-915.
7	BLŃKOWSKA A， BIERNAT M M， ŁACZMANSKI Ł，et al. Molecular patterns of resistance among Helicobacter pylori strains in south-western Poland［J］. Front Microbiol， 2018， 9： 3154.
8	林依依.福建地区幽门螺旋杆菌对常用抗生素耐药性研究及现行根除方案疗效评估［D］.福州：福建医科大学，2017.
9	COSME A， TORRENTE IRANZO S， MONTES- ROS M， et al. Helicobacter pylori antimicrobial resistance during a 5-year period （2013-2017） in northern Spain and its relationship with the eradication therapies［J］. Helicobacter， 2019， 24（1）： e12557.
10	庄少华，付金金，饶君. 炎症性肠病患者幽门螺杆菌感染情况及耐药性分析［J］. 中华医院感染学杂志， 2020， 30（7）： 1016-1020.
11	ZAMANI M， EBRAHIMTABAR F， ZAMANI V，et al.Systematic review with meta-analysis： the worldwide prevalence of Helicobacter pylori infection［J］. Aliment Pharmacol Ther， 2018， 47（7）： 868-876.
12	LIU J， WANG Y H， ZHAO Q H， et al. Prevalence and risk factors for Helicobacter pylori infection in southwest China： a study of health examination participants based on ¹³C-urea breath test［J］. Turk J Med Sci， 2017， 47（5）： 1456-1462.
13	CHOE J W， JUNG S W， KIM S Y， et al. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor， bismuth， amoxicillin， and metronidazole in Korea［J］. Helicobacter， 2018， 23（2）： e12466.
14	MEGRAUD F， COENEN S， VERSPORTEN A，et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption［J］. Gut， 2013， 62（1）： 34-42.
15	LIU W Z， XIE Y， LU H， et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection［J］. Helicobacter， 2018， 23（2）： e12475.
16	ZHANG Y X， ZHOU L Y， SONG Z Q， et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing： a prospective serial study［J］. World J Gastroenterol， 2015， 21（9）： 2786-2792.
17	HASHEMI S J， SHEIKH A F， GOODARZI H， et al. Genetic basis for metronidazole and clarithromycin resistance in Helicobacter pylori strains isolated from patients with gastroduodenal disorders［J］. Infect Drug Resist， 2019， 12： 535-543.
18	CALISKAN R， TOKMAN H B， ERZIN Y， et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics， including levofloxacin， in Northwestern Turkey［J］.Rev Soc Bras Med Trop，2015，48（3）： 278-284.
19	KIM K S， KANG J O， EUN C S， et al. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance［J］. J Korean Med Sci， 2002， 17（5）： 599-603.
20	YOON K H， PARK S W， LEE S W， et al. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea［J］. J Korean Med Sci， 2014， 29（9）： 1240-1246.
21	RASHEED F， CAMPBELL B J， ALFIZAH H， et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance［J］. Helicobacter， 2014， 19（5）： 387-399.
22	HANSOMBURANA P， ANANTAPANPONG S， SIRINTHORNPUNYA S， et al. Prevalence of single nucleotide mutation in clarithromycin resistant gene of Helicobacter pylori： a 32-months prospective study by using hybridization real time polymerase chain reaction［J］. J Med Assoc Thai， 2012， 95（）： S28-S35.
23	SOLCÀ N M， BERNASCONI M V， PIFFARETTI J C.Mechanism of metronidazole resistance in Helicobacter pylori： comparison of the rdxA gene sequences in 30 strains［J］. Antimicrob Agents Chemother，2000，44（8）： 2207-2210.
24	MIFTAHUSSURUR M， SHRESTHA P K， SUBSOMWONG P， et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal［J］. BMC Microbiol， 2016， 16（1）： 256.
25	TSHIBANGU-KABAMBA E， YAMAOKA Y. Helicobacter pylori infection and antibiotic resistance- from biology to clinical implications［J］. Nat Rev Gastroenterol Hepatol， 2021， 18（9）： 613-629.
26	TRESPALACIOS-RANGÉL A A， OTERO W， ARÉVALO-GALVIS A， et al. Surveillance of levofloxacin resistance in Helicobacter pylori isolates in bogotá-Colombia （2009-2014）［J］. PLoS One， 2016， 11（7）： e0160007.
27	WANG L H， CHENG H， HU F L， et al. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains［J］. World J Gastroenterol， 2010， 16（18）： 2272-2277.
28	GONG Y H， YUAN Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy［J］. Crit Rev Microbiol， 2018， 44（3）： 371-392.

Primer	Sequence（5'→3'）	Target fragment size（bp）
16S rRNA	F:ACGCATAGGTCATGTGCCTC	182
16S rRNA	R: GTGTCCGTTCACCCTCTCAG	182
23S rRNA	F: CCACAGCGATGTGGTCTCAG	425
23S rRNA	R: CTCCATAAGAGCCAAAGCCC	425
rdxA	F: TGAAACGCTTGAAAACACCC	851
rdxA	R: ATTTGAGCATGGGGCAGATTT	851
gyrA	F: TAGCTTATTCCATGAGCGTG	530
gyrA	R: TAAGACATGCACTAAAGCGT	530

Mutation form	Number of strains	Mutation rate（η/%）
A2143G	24	85.7
A2223G	3	10.7
A2142G + A2164G	1	3.6

Strain	Nucleotide mutation form	Amino acid mutation form
1	Insertion of T（64,65）	Frameshift mutation in amino acid 23
2	148 C→T	Premature stop codon (50)
4	352 G→T， Deletion of A（356）	118 A→S, frameshift mutation in amino acid 120
5	46 C→T，468 G→T	16 R→C，156 L→F
6	Insertion of G（134）， Insertion of C（135）	Frameshift mutation in amino acid 46
7	352 G→T，497 C→T，526 C→T	118 A→S，166 P→L，176 R→C
8	172 A→G，238 G→A，322 T→G，623 C→T	58 T→A，80 A→T，108 S→A，208 T→I
9	140 A→G	47 Y→C
10	Deletion of T（213）	Frameshift mutation in amino acid 72
11	90 C→A，148 C→T	30 S→R，Premature stop codon (50)
12	322 T→G，614 A→C	108 S→A，205 D→A
13	41 A→G，203 C→T，377 A→G，434 G→A，516 T→C	14 N→S，68 A→V，126 N→S，145 G→E，172 V→I
14	148 C→T	Premature stop codon (50)
16	352 G→A，610 G→A	118 A→T，204 V→I
17	317 C→T，488 G→A，168 G→A，393 A→G	106 P→L，163 G→D，56 M→I，131 R→K
18	8 T→C，47 G→A	3 F→S，16 R→H
19	202 G→A	68 A→T
20	47 G→A，192 A→T，293 G→A	16 R→H，64 K→N，98 G→N
21	419 G→A，536 A→G	140 C→Y，179 K→R
22	199 G→A，577 G→A	67 A→T，193 A→T
23	47 G→A，（61 A→G、62 T→C），89 G→A，462 G→A	16 R→H，21 M→A，30 S→N，154 M→I
24	89 G→A	30 S→N

Mutation form	Number of strains	Mutation rate（η/%）
N87K	23	65.7
N87I D91N D91G	1 3 1	2.9 8.5 2.9
N87K+D143E	1	2.9
—	6	17.1
“—”：No mutation.

[1]	Yao ZHENG,Mingxia FU,Weichen WANG,Weiwei CHEN,Yuchen HAN,Yu BAI,Jiajia AN. Effect of sodium selenite on biological behaviors of breast cancer doxorubicin-resistant MCF-7/ADR cells [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 410-417.
[2]	Yan LIU,Beizhen PAN,Jifei YANG,Xianyu ZHANG,Wenbo DING,Lingli SONG,Yundong ZHAO. Expression of quorum sensing related genes in multidrug-resistant Pseudomonas aeruginosa and its effects on biofilm formation and drug resistance [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 921-928.
[3]	Shuo ZHANG,Yunxiu XIA,Weiwei CHEN,Hongliang DONG,Bingjie CUI,Cuilan LIU,Zhiqiang LIU,Fei WANG,Jing DU. Effect of over-expression of NR2F2 on biological behaviors of human ovarian cancer SKOV3 cells [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 58-67.
[4]	Yanbin ZHANG,Guangye GUO,Caihua ZHENG,Xinyan LIU. Research progress in association between Helicobacter pylori and metabolic syndrome and its effect on occurrence and development of metabolic syndrome [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1757-1762.
[5]	Bingbing HU,Kangning LUO,Su PENG,Yuzhong ZHOU,Maoliang CHEN,Changhua LIU. Improvement effect of down-regulation of miR-208a on 5-FU resistance in colorectal cancer cells through targeting SFRP1 for mediating Wnt signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 947-955.
[6]	Zhibo XU,Xinmiao JIANG,Yuqi ZHEN,MA Quzhen BAI,Mengyao SUN,Xiuping MENG. Effect of chlorhexidine on drug resistance and pathogenicity of Enterococcus faecalis and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 676-681.
[7]	Ying ZHANG,Zhaohui WAN,Xianxun JIANG. Effect of over-expression of NDRG1 on resistance of castration-resistant prostate cancer resistant cell line C4-2/ENZA and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 708-717.
[8]	Linghui LIN,Na LI,Xiaoyan YIN,Xiaoling WANG,Yaping HU,Wei LIU,Rui FEI,Xinli TIAN. Bioinformatics anlysis based on three-dimensional structure of Helicobacter pylori hp0169 gene [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 739-748.
[9]	ERDEMUTU,Yanyan WANG,Yutong LI,Guilin CHEN,Junrui WANG. Comparison of drug resistance of MRSA clinical strains from respiratory tract and non-respiratory tract specimens and their molecular epidemiological characteristics [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 422-430.
[10]	Chunyan KANG,Xiuzhi ZHANG,Huicong ZHOU,Jie CHEN. Effect of downregulating proline-rich protein 11 expression on drug resistance of esophageal cancer drug resistant cell EC9706/DDP and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 113-119.
[11]	Jiaojiao XUE,Lei HAO,Yuxiu ZHANG,Heyang DAI,Lixia ZHANG,Shaowei GUO,Jingjing ZHANG,Yang LI,Qingxia LI. Effect of Huaier aqueous extract on breast cancer tamoxifen-resistant LCC2 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 714-721.
[12]	Yanchun QIN,Yanqiang HUANG,Gang LU,Ganrong HUANG,Huaying TANG,Yuanyuan DAI. Distribution characteristics of micrflora in various regions of intestinal tract of mice with chronic gastritis infected with Helicobacter Pylori andits mechannism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(2): 289-297.
[13]	Yanan MA,Bing TAN,Lei XU,Jiandong ZHANG. Detection of drug resistance genes of Acinetobacter baumannii in sputum samples of ICU patients by real-time fluorescence quantitative PCR method and its evaluation [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1623-1628.
[14]	Zhao JIN,Rushuai WANG,Zhaoyang WANG,zhanbiao HE,Fuming TIAN,Ruijun WANG. Effect of Parnassia palustris Linn extracts on Helicobacter pylori colonization in gastric mucosa and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(5): 1131-1138.
[15]	Qinghui WANG,Bo LI,Chuancui HU,Mingchao NIE,Xiaomei ZHENG. Effects of miR-107 on regulation of immune escape and taxol resistance of ovarian cancer cells [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 734-743.

Resistance rates of Helicobacter pylori to clarithromycin, metronidazole, and levofloxacin and mutation characteristics of their related drug resistance genes

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 13

References 28

Related Articles 15

Metrics

Comments

Recommended 10

Antibiotic	Number of drug- resistant strains	Drug resistance rate (η/%)
Clarithromycin	28	80
Metronidazole	35	100
Levofloxacin	35	100